About this trial
Because treatment decisions are usually based on a single measurement of the lipid panel at the time of an admission for an MI, the overarching objective of this project is to evaluate whether the measurement of LDL, non-HDL, and apoB values are reliable through all the duration of the hospitalization.
It will be a single-center, prospective, observational study will be conducted, including consecutive patients hospitalized for myocardial infarction at the Montreal Heart Institute.
Every patient at the Cardiac Care Unit will undergo non-fasting lipid panel testing at day 0 of their admission for Myocardial Infarction during the study period. Patients who consent to participate will have a 2nd non-fasting lipid panel drawn at day 2 of their admission.
Thereafter, the levels of the different lipid values from the panel will be compared between day 0, day 2, and 4-6 weeks after discharge.
Eligibility criteria
Qualifiers
Adult patients ≥18 years old
Hospitalized at the Cardiac Care Unit for Myocardial Infarction (either NSTEMI or STEMI)
Lipid panel performed on day 0 of admission
Willing to provide informed consent
Disqualifiers
None
Trial design
Treatments tested in this trial
- Lipid panel
Treatment groups
Sponsors and collaborators
Montreal Heart Institute
Lead sponsor
Novartis Pharmaceuticals
Collaborator